Finn G.
- Country
- Denmark
- Department
- Department of Cardiology
Research Overview
- Evaluation of Hydralazine Hydrochloride, Isosorbide Dinitrate, and Metformin Hydrochloride in Chronic Heart Failure with Reduced Ejection Fraction
- Efficacy and Safety Evaluation of Patisiran in Transthyretin Amyloidosis with Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 2 of 33 partner sites.
Specializations
Cardiac Amyloidosis Research
The investigator specializes in the study of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), exploring novel therapeutic approaches for this rare cardiac condition.
- Advanced treatment modalities for ATTR-CM
- Cardiac function assessment in amyloidosis
- Novel therapeutic compounds evaluation
Research extends to investigating both established and emerging treatments for cardiac amyloidosis manifestations.
Heart Failure Management
Focused on comprehensive treatment strategies for chronic heart failure with reduced left ventricular ejection fraction, particularly examining innovative therapeutic combinations.
- Optimized medication protocols
- Left ventricular function improvement
- Cardiovascular event prevention
Studies include evaluation of conventional and novel pharmaceutical interventions for heart failure management.
Cardiovascular Outcomes
Specializes in assessing cardiovascular clinical events and mortality outcomes in cardiac conditions, with emphasis on functional capacity measurements.
- 6-minute walk test assessments
- Cardiovascular mortality analysis
- Long-term patient monitoring
Expertise includes evaluation of treatment efficacy through comprehensive cardiovascular outcome measures.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.